BioNxt Solutions Inc.
BNXT
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -73.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -73.60% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -73.60% | |||
| SG&A Expenses | 99.05% | -3.82% | |||
| Depreciation & Amortization | -125.15% | -3.55% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 66.05% | -21.45% | |||
| Operating Income | -66.77% | 20.78% | |||
| Income Before Tax | -38.83% | 7.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.45% | 13.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.45% | 13.77% | |||
| EBIT | -66.77% | 20.78% | |||
| EBITDA | -68.26% | 21.08% | |||
| EPS Basic | -45.12% | 13.68% | |||
| Normalized Basic EPS | -23.21% | 5.08% | |||
| EPS Diluted | -45.12% | 13.68% | |||
| Normalized Diluted EPS | -23.21% | 5.08% | |||
| Average Basic Shares Outstanding | 1.75% | 0.32% | |||
| Average Diluted Shares Outstanding | 1.75% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||